Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Operating Leases (2019 - 2025)

ImmunityBio (IBRX) has disclosed Operating Leases for 7 consecutive years, with $33.4 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 3.95% to $33.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.4 million through Dec 2025, down 3.95% year-over-year, with the annual reading at $33.4 million for FY2025, 3.95% down from the prior year.
  • Operating Leases for Q4 2025 was $33.4 million at ImmunityBio, down from $34.1 million in the prior quarter.
  • The five-year high for Operating Leases was $52.1 million in Q2 2022, with the low at $16.6 million in Q1 2021.
  • Average Operating Leases over 5 years is $39.6 million, with a median of $38.0 million recorded in 2021.
  • The sharpest move saw Operating Leases surged 235.24% in 2021, then dropped 23.04% in 2024.
  • Over 5 years, Operating Leases stood at $37.1 million in 2021, then increased by 29.36% to $48.0 million in 2022, then fell by 5.63% to $45.2 million in 2023, then decreased by 23.04% to $34.8 million in 2024, then dropped by 3.95% to $33.4 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $33.4 million, $34.1 million, and $35.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.